Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Copenhagen | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to examine the effect of GLP-1 and other gut-secreted hormones (glucagon, GIP, grelin and PYY) on food-intake, appetite and glucose metabolism after Roux-en-Y gastric bypass surgery.
To do this the effect of combined GLP-1 receptor blockade by Exendin 9-39 and DPP-4-inhibition will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Saline | Placebo Comparator | Mixed meal test and ad libitum meal test duing infusion of saline |
|
| Exendin 9-39 | Experimental | Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min |
|
| DPP-4 Inhibition | Experimental | Mixed meal test and ad libitum meal test during intake of sitagliptin 100 mg * 2 |
|
| Exendin 9-39 / DPP 4-Inhibition | Experimental | Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min and intake of sitagliptin 100 mg * 2 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| exendin 9-39 | Drug | Exendin 9-39 is a specific GLP-1 receptor antagonist |
|
| Measure | Description | Time Frame |
|---|---|---|
| Ad libitum food intake (changes in food intake) | Evaluated by changes in food intake between the placebo day and the day with both administration of exendin 9-39 and DPP 4 Inhibitor | 3-12 month after RYGB |
| Measure | Description | Time Frame |
|---|---|---|
| Glucose metabolism (iAUC of glucose and c-pep after a meal) | Evaluated by iAUC of glucose and c-pep after a meal | 3-12 month after RYGB |
| Gut-derived hormone profiles (iAUC of GLP-1, PYY, GIP and glucagon after a meal) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sten Madbad, MD, DMSc | Hvidovre University Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hvidovre University Hospital | Hvidovre | DK-2650 | Denmark |
Not provided
| ID | Term |
|---|---|
| D009767 | Obesity, Morbid |
| ID | Term |
|---|---|
| D009765 | Obesity |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C083773 | exendin (9-39) |
| D000068900 | Sitagliptin Phosphate |
| ID | Term |
|---|---|
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| sitagliptin | Drug | DPP-4 Inhibition |
|
|
| Placebo | Other | Saline |
|
Evaluated by iAUC of GLP-1, PYY, GIP and glucagon after a meal
| 3-12 month after RYGB |
| Appetite measurement (VAS-scores) | Evaluated by VAS-scores | 3-12 month after RYGB |
| D009750 |
| Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011719 |
| Pyrazines |